World Investment Advisors Raises Stake in Medtronic PLC $MDT

World Investment Advisors increased its stake in shares of Medtronic PLC (NYSE:MDT) by 5.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 167,403 shares of the medical technology company’s stock after buying an additional 8,961 shares during the period. World Investment Advisors’ holdings in Medtronic were worth $15,700,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in MDT. Lodestone Wealth Management LLC bought a new position in Medtronic in the 4th quarter worth about $27,000. Anfield Capital Management LLC increased its stake in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Board of the Pension Protection Fund bought a new position in Medtronic in the 4th quarter worth about $29,000. GoalVest Advisory LLC bought a new position in Medtronic in the 4th quarter worth about $29,000. Finally, Valley Wealth Managers Inc. bought a new position in Medtronic in the 3rd quarter worth about $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of Medtronic stock opened at $76.85 on Wednesday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $98.66 billion, a PE ratio of 21.41, a price-to-earnings-growth ratio of 1.77 and a beta of 0.62. The business’s 50-day moving average price is $85.98 and its 200-day moving average price is $94.01. Medtronic PLC has a 12 month low of $74.40 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.7%. Medtronic’s dividend payout ratio is 79.11%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MDT shares. Citigroup decreased their target price on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Argus decreased their target price on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Mizuho decreased their target price on Medtronic from $125.00 to $120.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. JPMorgan Chase & Co. decreased their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $95.00 target price on shares of Medtronic in a research note on Thursday, April 23rd. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $107.80.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors appear to be reacting favorably to relief from a long-running legal overhang after a False Claims Act case was dismissed, which removes a source of headline risk for Medtronic and could improve sentiment toward the stock. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Fresh updates on Medtronic’s cardiac rhythm management and broader device pipeline are reinforcing hopes for stronger product momentum, especially around newer ablation and diabetes-related offerings. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Orchestra BioMed said enrollment in the BACKBEAT pivotal trial is on track to finish by the end of Q3 2026, with data expected in Q2 2027 and a planned FDA filing afterward. Because Medtronic is the strategic collaborator, this supports a longer-term growth and pipeline narrative. Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
• Neutral Sentiment: Medtronic also announced a California site closure as part of restructuring and portfolio consolidation in cardiovascular businesses. That may help efficiency over time, but it is more of an operational cleanup than an immediate stock catalyst. Medtronic to close California site amid restructuring
• Negative Sentiment: Medtronic has still faced recent pressure from broader healthcare-sector rotation and earlier reports of a stock decline, suggesting investors are balancing the positive legal and pipeline news against a still-soft technical backdrop. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).